{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:41:28Z","timestamp":1777934488139,"version":"3.51.4"},"reference-count":8,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T00:00:00Z","timestamp":1607817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:p>Current recommendations for prophylaxis of Pneumocystis jirovecii pneumonia in oncology patients include administration of trimethoprim\/sulfamethoxazole (TMP\/SMX) three times weekly or the same total weekly dose given daily. The primary objective of this study was to evaluate the efficacy of two consecutive days per week of TMP\/SMX for prevention of Pneumocystis jirovecii pneumonia (PJP) in pediatric oncology patients. A retrospective cohort, single-center analysis was conducted in oncology patients 21\u2009years and younger who received TMP\/SMX for PJP prophylaxis between February 1, 2013 and July 31, 2017. Changes to the prophylaxis regimen were documented and analyzed. A total of 322 patients received TMP\/SMX on two consecutive days per week for PJP prevention, of whom four had confirmed PJP (1.3%). Neutropenia was the most common reason for switching to alternative prophylaxis therapy (11.5%). Two consecutive prophylaxis days with TMP\/SMX may be insufficient to prevent PJP in children with hematologic malignancies. Neutropenia remains a barrier for TMP\/SMX use for PJP prophylaxis. Further studies to compare PJP incidence in children receiving alternative prophylaxis regimens should be considered.<\/jats:p>","DOI":"10.1177\/1078155220979046","type":"journal-article","created":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T02:21:15Z","timestamp":1607912475000},"page":"1936-1939","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Twice weekly prophylaxis with trimethoprim\/sulfamethoxazole for\n                    <i>Pneumocystis jirovecii<\/i>\n                    pneumonia in pediatric oncology patients"],"prefix":"10.1177","volume":"27","author":[{"given":"Monica","family":"Awad","sequence":"first","affiliation":[{"name":"Sutter Medical Center, Sacramento, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9336-5644","authenticated-orcid":false,"given":"Caroline M","family":"Sierra","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma Linda, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elhaam","family":"Mesghali","sequence":"additional","affiliation":[{"name":"Riverside University Health System, Moreno Valley, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Bahjri","sequence":"additional","affiliation":[{"name":"Sutter Medical Center, Sacramento, CA, USA"},{"name":"Department of Pharmaceutical and Administrative Sciences, Loma Linda University School of Pharmacy, Loma Linda, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,12,13]]},"reference":[{"key":"bibr1-1078155220979046","volume-title":"Red book: 2018 report of the committee on infectious diseases","author":"American Academy of Pediatrics"},{"key":"bibr2-1078155220979046","unstructured":"Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the use of antiretroviral agents in pediatric HIV infection, http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/pediatricguidelines.pdf (accessed 16 December 2019)."},{"key":"bibr3-1078155220979046","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706253162604"},{"key":"bibr4-1078155220979046","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21774"},{"key":"bibr5-1078155220979046","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-1360"},{"key":"bibr6-1078155220979046","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181fd6fca"},{"key":"bibr7-1078155220979046","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.10.021"},{"key":"bibr8-1078155220979046","doi-asserted-by":"publisher","DOI":"10.3345\/kjp.2016.59.6.252"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220979046","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220979046","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220979046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:24:18Z","timestamp":1777688658000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220979046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,13]]},"references-count":8,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1177\/1078155220979046"],"URL":"https:\/\/doi.org\/10.1177\/1078155220979046","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,13]]}}}